NEW YORK & NOIDA, India--(BUSINESS WIRE)--HCLTech, a leading global technology company, today reported financial results for the fourth quarter and year ended March 31, 2023. The company reported full year revenue $12.6 billion, up 9.6% YoY on the back of strong deal pipeline across its ...
HCLTech positioned as a Leader in IDC MarketScape Worldwide Application Modernization Services Vendor Assessment, 2023 Learn more HCLTech Positioned As A Leader In The Forrester Wave™: Cloud Migration And Managed Service Partners In Asia Pacific, Q4 2022 ...
data analytics and engineering solutions. With eight partner programs and over 34,000 trained resources across 13 practices, our team has the skills and experience to deliver results. Partnering with over 260 global clients across multiple industries, we have earned our reputation as an AWS Premier...
In addition to this, Phenibut is also an anti-anxiety nootropic supplement with the same or even better results. Both nootropics are white powders that act on GABA receptors in the brain and improve mood, but their similarities end there. ...
reaction was found to be 1 : 5 and the oxidation products were identified by spectral analysis. The conjugate free acid C6H5SO2NHCl of CAB is postulated as the reactive oxidizing species. The observed results have been explained by plausible mechanism and the related rate law ...
(ZAR 46.6 million)1in Q1 2024, compared to a loss of $1.4 million (ZAR 23.9 million)1in Q1 2023. With the divisional turnaround complete, initiatives to grow the Consumer Division are yielding positive results with revenue increasing 13% in ZAR, off a reduced cost base and in a ...
our team has the skills and experience to deliver results. Partnering with over 260 global customers across multiple industries, we have earned our reputation as an AWS Premier Consulting Partner and Managed Service Provider. With the CloudSMART framework at our core, we help enterprises seamlessly ...
Alectinib hydrochloride is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. Also is an intermediate of Alectinib (C183360), a highly ...